Industries > Pharma > Next-Generation Antibody Therapies: World Industry and Market 2014-2024
Next-Generation Antibody Therapies: World Industry and Market 2014-2024
Antibody technology – discover R&D, business analysis, and revenue forecasts
What’s the future of technologies harnessing therapeutic antibodies? Now you can get technological and business predictions. Stay ahead for data, helping your authority. There you explore developmental trends, sales results, opportunities, and revenue forecasts.
Visiongain’s new report shows you what’s possible for monoclonal antibodies (mAbs) and other immunotechnology for pharmaceuticals. Avoid missing out. Instead find progress in that medical industry and market, discovering the expected progress and gains.
Read on to explore those drugs, seeing how high revenues can go.
Forecasts and other information showing lucrative biopharmaceutical possibilities
The updated study gives you sales predictions to 2024 at overall world, submarket, product, and regional level. For those treatments – antibodies and variants – you investigate where money lies.
Hear what’s possible. Also avoid struggles to find information. Besides revenue forecasting, our new work shows historical performance, recent results, growth rates, and market shares. There you also gain feel for developments (R&D) in those medicines.
So discover 74 tables, 58 charts, and three interviews with authorities in that industry, helping your research, analyses, and decisions.
And the following sections explain what our investigation gives you.
Forecasting of that world market and its main segments – what’s likely to happen?
What’re the secrets of that biomedical industry’s progress? Discover in our report overall world revenue to 2024 for those immunological products.
Also find individual revenue predictions to 2024 for five therapeutic submarkets at world level:
• Antibody-drug conjugates (ADCs)
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and antibody-like proteins (ALPs)
• Biosimilar antibodies (biosimilars).
There you assess outlooks for sales expansion, hearing where you could gain. Our work investigates R&D, competition and rising sales – technological and commercial possibilities.
You explore successes, developments and competition for those biological drugs (biologics). And you find leading therapeutic agents’ selling potentials.
Revenue predictions for top therapeutics in that biotechnological segment
How will individual drugs perform to 2024 at world level? Our study forecasts revenues of six products:
And these four biosimilar agents:
There you find drugs and years with highest predicted sales. Also you examine competitors. You see what’s happening, then, understanding, challenges, trends, and outlooks.
That work also shows geographical revenue predictions.
Healthcare in regional markets – what outlooks for follow-on antibodies?
In developed and developing countries, many opportunities for producers and sellers of next-generation antibody products will occur from 2014 to 2024. See where and how.
Our analyses show you individual revenue forecasts to 2024 for four regional markets:
• United States (US)
• European Union (EU)
• Rest of world (grouped).
There you find countries with highest revenues, demand, and potential sales growth. Explore progress, needs and opportunities.
What events, challenges and expectations affect that industry and market? Our work shows you, discussing events, policies, and trends influencing that pharma field.
Forces affecting developers, producers, and sellers of those immunotechnological agents
The report explains issues and events affecting that industry and market from 2014, including these:
• Improved monoclonal antibodies, Fab fragments, and receptor constructs
• Drug approvals and outlooks
• Acquisitions by big pharmaceutical companies
• R&D pipelines for new therapies – e.g. CD19, CD20, and HER targeting – including biosuperiors
• Cancer treatments – ovarian, breast, prostate, lymphoma, and leukaemia.
And you explore these influences, among others:
• Modifying amino acids in the Fc domain
• Recombinant antibody mixtures – improving therapeutic proteins
• Single-chain variable fragment platforms
• Product lifecycle management and regulatory affairs
• Contract manufacturing organisations (CMOs) investing in next-generation antibody technologies.
See too how R&D lets companies benefit patients. You find what stimulates and restrains players in that sector, and affects its results.
New antibody technology and applications – companies and 2018 market value
From 2014, novel treatments and demands from patients, doctors, and payers encourage investments, medical advances, and higher revenues from immune-based technologies.
And what happens next? Our study predicts that world market will reach $6.7bn in 2018.
There you examine activities of many companies, including these:
• Seattle Genetics
• Kyowa Hakko Kirin
You find 180 organisations covered. You also get three interviews with leaders in that industry. Discover what participants do, say, and think, helping you stay ahead.
Ways Next-Generation Antibody Therapies: World Industry and Market 2014-2024 helps
Through knowledge such as this, our new report helps you gain recognition for insight:
• Revenues there to 2024 at world level, for 5 submarkets, and 10 products – assess outlooks for production, marketing, and sales
• Forecasts to 2024 for four regional markets – investigate leading regions and countries for revenues and sales expansion
• Prospects for established competitors, rising companies, and new entrants – explore portfolios, results, strategies, R&D, and outlooks for success.
Information found nowhere else, helping your searches, analyses, and planning
Our study gives independent analysis. There you receive competitive intelligence found only in our work, finding where money and progress lie. You explore the business possibilities.
With that data you’re less likely to fall behind in knowledge or miss opportunity. Being free to choose, you find with our report how you could save time and effort. And also help your plans, decisions, influence, and competing.
Our new report is for everyone analysing medical biotechnology. There you explore crucial trends, finding sales potentials from 2014. So avoid missing out – please order now.
To see sample pages of this report please click here
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6